Phenomix Company Description
Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and cancer. The biotechnology firm's small-molecule drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. Phenomix submitted an IPO filing in early 2008 to help fund its development and commercialization efforts.
View the Comprehensive Company Description for Phenomix
The Company Description provides a historical perspective of Phenomix's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Phenomix's evolution in the marketplace.
